Search results
Nail Psoriasis
Health via Yahoo News· 2 weeks agoSome other autoimmune diseases, like rheumatoid arthritis (RA) and lupus, can be associated with nail changes that may resemble those seen in psoriatic ...
Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief
Verywell Health via Yahoo News· 1 week agoBut after two pregnancies and the emergence of two new autoimmune conditions, my psoriasis became...
What To Know and Do About Arthritis Pain
Health via Yahoo News· 1 week agoArthritis is a condition that causes pain, stiffness, and inflammation in your joints. Fortunately, medications and home remedies can help relieve pain.
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...
The Parsons Sun· 2 weeks ago- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)
6 Signs of an Autoimmune Disease That Can Be Easy to Miss
Self via Yahoo News· 2 weeks agoA few other notable autoimmune conditions that can cause joint issues? Lupus (one type that attacks...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 15 hours ago- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment
AbbVie (NYSE:ABBV) vs. Cosmo Pharmaceuticals (OTC:CMOPF) Head to Head Review
ETF DAILY NEWS· 4 days agoAbbVie (NYSE:ABBV – Get Free Report) and Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses ...
Potential Precursor Lesion to Adrenal Tumors Identified
Medscape· 6 days agoCortisol-producing adenomas (CPAs) are preceded by the development of steroids-producing nodules...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 1 week agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...